- Global Pharma News & Resources

Global Fluorescent in Situ Hybridization Probe Market Report to 2027: Featuring Thermo Fisher Scientific, Roche Holdings, PerkinElmer and Sysmex Among Others -

DUBLIN--(BUSINESS WIRE)--The "Global Fluorescent in Situ Hybridization Probe Market: Analysis By Product, By Technology, By End User, By Application, By Region Size And Trends With Impact Of COVID-19 And Forecast Up To 2027" report has been added to's offering.

The global fluorescent in situ hybridization (FISH) probe market in 2021 was valued at US$1.40 billion. The market value is expected to reach US$2.24 billion by 2027.

A Fluorescent in Situ Hybridization (FISH) Probe refers to a sub-atomic cytogenetic technique that uses fluorescent probes to visualize genetic materials. They are used to identify structural and numerical abnormalities in chromosomes, therapeutic drug monitoring and the identification of rare genetic diseases.

In comparison to the traditionally used standard cytogenetic (cell gene) tests, FISH tests can identify minute genetic changes that are usually missed under the microscope. These probes are therefore widely used for the diagnosis, prediction of outcomes and clinical management of cancer and genetic disorders. The market is expected to grow at a CAGR of 8.21% during the forecast period of 2022-2027.

Market Dynamics

Growth Drivers

  • Growing Aging Population
  • Rapid Urbanization
  • Increasing Prevalence of Cancer and Genetic Disorders
  • Growing Requirements For In Vitro Diagnostics (IVD) Testing
  • Technological Advancements
  • Advantages of FISH Probe


  • Rising Pathologist Shortages
  • Lack Of Efficient Digitalization Solutions And Advanced Automation Capabilities

Market Trends

  • Escalating Demand for Big Data
  • FISH Automation

Market Segmentation Analysis:

  • By Product: The report provides the bifurcation of the market into two segments based on the product: instrument/ software and consumables. In 2021, instrument/ software segment held a major share in the market. On the other hand, the consumables segment is expected to grow at a significant CAGR in the forthcoming years, owing to the wide range of consumables used in the detection.
  • By Technology: The report provides the bifurcation of the market into three segments based on the technology: Q FISH, Flow FISH and others. In 2021, Q FISH technology segment held a major share in the market. This was being followed by Flow FISH technology segment. Growing demand for In Vitro Diagnostics (IVD) testing and targeted medicines around the world is also propelling this segment forward.
  • By End User: The report provides the bifurcation of the market into three segments based on the end user: clinical procedures, research and companion diagnostics. In 2021, clinical procedures segment held a major share in the market. This was being followed by research segment. The high share of clinical procedures can be attributed to the large number of diagnostic centers and their widespread use of FISH for diagnostic and prognostic purposes. The rise in the number of incidents related to genetic disorders, solid tumors, leukemia, autism, and other syndromes is predicted to stimulate market demand for FISH Probe over the forecast period, thus boosting the growth of clinical procedures segment.
  • By Application: The report provides the bifurcation of the market into two segments based on the application: cancer diagnostics and other. In 2021, cancer diagnostics segment held a major share of in the market. The increase in the incidence rate of cancer cases is anticipated to drive the growth. Rising unhealthy lifestyle, aging population, health conditions, and environment are leading factors for causing cancers. With the rise in the number of cancer cases, the need for in FISH situ hybridization techniques for rapid and efficient diagnosis is high.
  • By Region: The report provides insight into the FISH Probe market based on the geographical operations, namely North America, Europe, Asia Pacific, Middle East & Africa and Latin America. North America held the major share in the market, owing to high incidence rate of genetic disorders leading to birth defects, developmental disabilities, and other metabolic syndromes.
  • Within North America, the US is leading the market, due to the presence of a considerable number of market players and incentivized research projects by the regional government. Whereas, in the Europe region, Germany is dominating the market due to growing pharmaceutical and biotechnology sectors.

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Bio-rad Laboratories, Inc.
  • Roche Holdings AG
  • Bio-Techne Corporation
  • Abbott Laboratories
  • PerkinElmer, Inc.
  • Biocare Medical LLC
  • Agilent Technologies
  • Sysmex Corporation
  • Abnova Corporation
  • LGC Group
  • Genemed Biotechnologies, Inc.
  • Danaher Corporation

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 09-Dec-2022